Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Breast Cancer — Options & Clinical Trial Reference
Biomarker-guided reference covering hormone receptor (ER/PR), HER2 / HER2-low IHC/ISH, BRCA1/2, PIK3CA, AKT1/PTEN, ESR1, and recruiting clinical trials.
Key Biomarkers & Decision Factors:
versionstatuspending_status_valuesbiomarkers
versionstatuspending_status_valuesbiomarkers
Unranked Guideline & FDA-Label Option Categories (64 total)
| Option / Pathway | Category | Primary Sources |
|---|---|---|
| Breast and axillary surgery planning | Local care | nci |
| Postoperative radiation review | Local care | nci |
| Adjuvant endocrine treatment | Endocrine therapy | nci |
| Preoperative aromatase inhibitor review | Endocrine therapy | nci |
| Early chemotherapy review | Chemotherapy | nci |
| Abemaciclib plus adjuvant endocrine therapy | Adjuvant targeted therapy | abema, abema_label, verzenio_coverage_20261109 |
| Ribociclib plus adjuvant aromatase inhibitor | Adjuvant targeted therapy | ribo_adj, ribo_label, kisqali_coverage_20261109 |
| Adjuvant olaparib | Adjuvant targeted therapy | olaparib |
| T-DXd followed by taxane, trastuzumab and pertuzumab | Neoadjuvant HER2 therapy | tdxd_early, enhertu |
| Trastuzumab, pertuzumab and chemotherapy before surgery | Neoadjuvant HER2 therapy | perjeta |
| Trastuzumab, pertuzumab and adjuvant chemotherapy review | Adjuvant HER2 therapy | perjeta |
| T-DXd after residual invasive HER2-positive disease | Post-neoadjuvant HER2 therapy | tdxd_early, enhertu |
| Pembrolizumab with chemotherapy, then postoperative pembrolizumab | Perioperative TNBC therapy | kn522_label, kn522, kn522_os |
| Complete planned postoperative pembrolizumab | Post-neoadjuvant TNBC therapy | kn522_label |
| Adjuvant capecitabine for residual TNBC | Post-neoadjuvant chemotherapy | createx, dpyd |
Recruiting Clinical Trials (43 curated)
| NCT ID | Study Title | Phase |
|---|---|---|
| NCT01042379 | I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) | PHASE2 |
| NCT03606967 | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer | PHASE2 |
| NCT03936478 | A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI) | PHASE2 |
| NCT03990896 | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | PHASE2 |
| NCT04084730 | Ultra-Short External Beam-Based Accelerated Partial Breast Irradiation (APBI): A Phase II Toxicity Study Nested With a Non-inferiority Assessment of APBI in New Patient Cohorts | PHASE2 |
| NCT04722692 | Sentinel Lymph Node Biopsy in Ductal Cancer in Situ or Unclear Lesions of the Breast and How to Not do it. An Open-label, Phase 3, Randomised Controlled Trial. (SentiNot 2.0). | PHASE3 |
| NCT04768426 | Phase II Trial of Circulating Tumor DNA Monitoring During Adjuvant Capecitabine in Patients With Triple-negative Breast Cancer and Residual Disease Following Standard Neoadjuvant Chemotherapy | PHASE2 |
| NCT04787042 | A First-In-Human Phase 1/2 Open-Label Study of Intravenous ST-067, Subcutaneous ST-067 with or Without Obinutuzumab Pre-Treatment, and ST-067 in Combination with Pembrolizumab in Subjects with Advanced Solid Malignancies | PHASE1/PHASE2 |
| NCT04802759 | A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) | PHASE1/PHASE2 |
| NCT04899908 | A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone | PHASE2 |
| NCT05013255 | Pioglitazone Therapy Targeting Fatigue in Breast Cancer | PHASE2 |
| NCT05232916 | A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) | PHASE3 |